iScience (Aug 2020)
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
- Hong Kwan Kim,
- Je-Gun Joung,
- Yoon-La Choi,
- Se-Hoon Lee,
- Byung Jo Park,
- Yong Soo Choi,
- Daeun Ryu,
- Jae-Yong Nam,
- Mi-Sook Lee,
- Woong-Yang Park,
- Soohyun Hwang,
- Hongui Cha,
- Hong Sook Kim,
- Sanghyuk Lee,
- Yeonjoo Jung,
- Jong Eun Lee,
- Junsang Doh,
- Soonmyung Paik,
- Jung Hee Kang,
- Jinseon Lee,
- Jhingook Kim
Affiliations
- Hong Kwan Kim
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
- Je-Gun Joung
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
- Yoon-La Choi
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Se-Hoon Lee
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea
- Byung Jo Park
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
- Yong Soo Choi
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
- Daeun Ryu
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
- Jae-Yong Nam
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
- Mi-Sook Lee
- Laboratory of Cancer Genomics and Molecular Pathology, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
- Woong-Yang Park
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
- Soohyun Hwang
- Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Hongui Cha
- Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea
- Hong Sook Kim
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Sanghyuk Lee
- Department of Life Science, Ewha Womans University, Seoul, Korea; Ewha Research Center for Systems Biology, Ewha Womans University, Seoul, Korea
- Yeonjoo Jung
- Ewha Research Center for Systems Biology, Ewha Womans University, Seoul, Korea
- Jong Eun Lee
- DNA Link Inc., Seoul, Korea
- Junsang Doh
- Department of Materials Science and Engineering, Seoul National University, Seoul, Korea
- Soonmyung Paik
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea
- Jung Hee Kang
- Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
- Jinseon Lee
- Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; Corresponding author
- Jhingook Kim
- Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; Corresponding author
- Journal volume & issue
-
Vol. 23,
no. 8
p. 101386
Abstract
Summary: Exome and transcriptome analyses of clinically homogeneous early-stage never-smoker female patients with lung adenocarcinoma were performed to understand tumor-T cell interactions and immune escape points. Using our novel gene panels of eight functional categories in the cancer-immunity cycle, three distinct subgroups were identified in this immune checkpoint blockade-refractory cohort by defective gene expression in two major domains, i.e., type I interferon production/signaling pathway and antigen-presenting machinery. Our approach could play a critical role in understanding immune evasion mechanisms, developing a method for effective selection of rare immune checkpoint blockade responders, and finding new treatment strategies.
